Nice work Edward Christopher "Chris" Dee, MD & team!

In well-selected patients, ablative RT may improve outcomes in locally recurrent pancreas cancer.

Dutch ARCADE RCT assessing this strategy, & Hyun Kim also developing trial through NRG.

Edward Christopher "Chris" Dee, MD - we need you in GI rad onc!

Our Rad Onc Purple Beam Team, led by Dr. Todd Aguilera MD PhD and Minda Hill, came in third place for overall fundraising for the #PanCANPurpleStride PanCAN! Dr. Aguilera also placed second for individual fundraising!

Thank you to Neil Newman for giving a lecture at RadOncUH University Hospitals CWRU School of Medicine on the management of hepatocellular carcinoma.

If radiation had an accelerated approval pathway - also based on surrogate endpoints like response rate - it would probably be approved in most settings.

Which doesn’t make sense. Just FYI.

Nice pre-ASCO ESOPEC discussion Krishan Jethwa & Daniel Catenacci, Daniel Catenacci you know our rad onc talking points well 😂

Let's wait to see results. Folks also thought for sure FOLFIRINOX would be winner in PREOPANC2, and OS curves turned out superimposable.

I do think among GI cancers, HCC is a site where protons could be beneficial due to more sparing of non-target liver.

Also suggested in Ted Hong 2015 JCO paper and our MGH retrospective analysis.

Hope NRG GI003 proton v photon RCT finishes accruing.

Protons are just 1 tool

Finally! Look forward to this presentation at #ASCO24

Are there any validation studies for wearables in oncology?

Shaalan Beg MD MBA FASCO

This series is so good
Best way to learn critical appraisal
sensible-med.com/p/improving-yo…

Common Sense Oncology leadership team is having its first annual meeting next week in Montreal. Our opening plenary session will be open to all CSO members. Join us by zoom for the LIVE plenary session with these leaders in our field.
Register for zoom link here-

That only 4% of cancer survivors adhered to lifestyle/nutrition guidelines is an indictment of guidelines, that are largely based on beliefs rather than science.

The field should have some humility. These people just survived cancer. Let them live.

jamanetwork.com/journals/jamao…

Important paper showing overall positive trend with 42% of first authors = female in 2019 (although wide range between countries).

Agree that WHY is the big question, so need to know what is the proportion of M vs. F oncologists in each country? How many are doing research and

Dr. Nina Niu Sanford Great points. Survey attrition is an absolute killer and almost certainly biases the results.

The challenge is mitigating attrition, which is hard. IMO #1 goal should be instrument efficiency.

So tempting to deploy multiple surveys, but keep it simple: less can be more.

Dr. Nina Niu Sanford We've looked into the topic more closely for PRIME-ROSE earlier this year as we need to pick an hrQoL tool for our expansion cohort- write-up still needs finalising and the buck is totally with me on that one I'm afraid...

As a patient, QOL is a very important consideration and metric for me but I also acknowledge the difficulty of getting these metrics right.

I’m going to call myself out here because my own QOL reporting has been wildly subjective at times and is often the most off base when I’m

Dr. Nina Niu Sanford Appreciate your💡on this topic! PROs critical but undervalued, HRQOL endpoint design/reporting remains unregulated in many prospective studies. U.S. FDA and ISOQOL guidance published, we need more #radonc #ONCSM pt-centered trial design from the ground up

Dr. Nina Niu Sanford Can’t agree more. In multiple myeloma (and hem malignancies broadly), the quality of reporting is extremely poor, with ~2/3rd not even reporting a hypothesis. It’s mostly a fishing expedition with ?picking/choosing positive data. Hope reporting with improve now that consensus

Totally agree, important tweet.

Analyzing QoL data is challenging, powering for it kind of seems impossible (I know its not).

Very interesting to review the data if you know the patients personally from clinic, too.